Avanafil - a further step to tailoring patient needs and expectations

Area of Science:

• Pharmacology
• Urology

Background:

• Phosphodiesterase type 5 inhibitors (PDE5Is) are first-line treatments for erectile dysfunction (ED).
• A significant portion of ED patients experience treatment dissatisfaction or lack of response to existing PDE5Is.
• Avanafil is a recently developed second-generation PDE5I for ED treatment.

Purpose of the Study:

• To review the clinical development and efficacy of avanafil for erectile dysfunction.
• To analyze the pharmacokinetics and pharmacodynamics of avanafil.
• To compare avanafil's safety and efficacy profile with existing PDE5Is.

Main Methods:

• Systematic literature search of English-language studies up to May 2016 in the Medline database.
• Inclusion of pivotal clinical development studies and placebo-controlled randomized clinical trials (RCTs) of avanafil in ED patients.
• Analysis of pharmacokinetic and pharmacodynamic studies related to avanafil.

Main Results:

• Avanafil demonstrates efficacy comparable to existing PDE5Is in both treatment-naïve and previously treated ED patients.
• Avanafil is effective approximately 15 minutes after dosing, uniquely approved for use 15-30 minutes before sexual activity.
• High selectivity for the PDE5 isoenzyme results in a lower incidence of drug-related side effects compared to other PDE5Is.

Conclusions:

• Avanafil is a potent and highly selective PDE5I for ED treatment.
• Its rapid onset of action and favorable side effect profile offer a valuable alternative for ED management.
• Avanafil provides comparable efficacy to existing PDE5Is with potential for improved patient satisfaction.